1
|
Veiner HL, Gorbatov R, Vardi M, Doros G, Miller-Lotan R, Zohar Y, Sabo E, Asleh R, Levy NS, Goldfarb LJ, Berk TA, Haas T, Shalom H, Suss-Toby E, Kam A, Kaplan M, Tamir R, Ziskind A, Levy AP. Pharmacogenomic interaction between the Haptoglobin genotype and vitamin E on atherosclerotic plaque progression and stability. Atherosclerosis 2015; 239:232-9. [PMID: 25618031 DOI: 10.1016/j.atherosclerosis.2015.01.008] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/09/2014] [Revised: 12/29/2014] [Accepted: 01/07/2015] [Indexed: 02/07/2023]
Abstract
OBJECTIVE Homozygosity for a 1.7 kb intragenic duplication of the Haptoglobin (Hp) gene (Hp 2-2 genotype), present in 36% of the population, has been associated with a 2-3 fold increased incidence of atherothrombosis in individuals with Diabetes (DM) in 10 longitudinal studies compared to DM individuals not homozygous for this duplication (Hp 1-1/2-1). The increased CVD risk associated with the Hp 2-2 genotype has been shown to be prevented with vitamin E supplementation in man. We sought to determine if there was an interaction between the Hp genotype and vitamin E on atherosclerotic plaque growth and stability in a transgenic model of the Hp polymorphism. METHODS AND RESULTS Brachiocephalic artery atherosclerotic plaque volume was serially assessed by high resolution ultrasound in 28 Hp 1-1 and 26 Hp 2-2 mice in a C57Bl/6 ApoE(-/-) background. Hp 2-2 mice had more rapid plaque growth and an increased incidence of plaque hemorrhage and rupture. Vitamin E significantly reduced plaque growth in Hp 2-2 but not in Hp 1-1 mice with a significant pharmacogenomic interaction between the Hp genotype and vitamin E on plaque growth. CONCLUSIONS These results may help explain why vitamin E supplementation in man can prevent CVD in Hp 2-2 DM but not in non Hp 2-2 DM individuals.
Collapse
Affiliation(s)
- Hilla-Lee Veiner
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
| | - Rostic Gorbatov
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
| | - Moshe Vardi
- Harvard Clinical Research Institute, Boston, MA, USA; Boston University School of Public Health, Boston, MA, USA
| | - Gheorghe Doros
- Harvard Clinical Research Institute, Boston, MA, USA; Boston University School of Public Health, Boston, MA, USA
| | - Rachel Miller-Lotan
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
| | - Yaniv Zohar
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
| | - Edmond Sabo
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
| | - Rabea Asleh
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
| | - Nina S Levy
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
| | - Levi J Goldfarb
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
| | - Thomas A Berk
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel; University of Toronto Faculty of Medicine, Toronto, Canada
| | - Tali Haas
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
| | - Hadar Shalom
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
| | - Edith Suss-Toby
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
| | - Adi Kam
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
| | | | | | | | - Andrew P Levy
- Technion Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel.
| |
Collapse
|